Welcome to the inaugural edition of our annual Mechanism of Action Magnifier™! The Magnifier series is an exclusive supplement brought to you by the publishers of Personalized Medicine in Oncology (PMO) to delve into the biochemical interaction through which an oncology drug produces its pharmacological effect.
Dx Profiler: Can Metastatic Cancer with Diagnostic Ambiguity Be Treated Based on Mutational Status Alone?
- Review of the Initial Results from Basket Trials
- Implications of Initial Results in Patients with Metastatic Cancer and Diagnostic Ambiguity
- Improving Diagnostic Certainty: The Role of Molecular Assays in Challenging Cases
- Performance of the CancerTYPE ID Molecular Classifier
Mechanism of Pathway: Phosphatidylserine, an Immune-Modulating Checkpoint, Ushers in the Next Wave of Immuno-Oncology Targets
- Phosphatidylserine (PS) is an immune checkpoint distinct from PD-1/PD-L1, CTLA-4, and other antagonists or agonists of T-cell activation
- Tumors compromise the body’s normal immunosuppressive process of clearance/disposal of dying cells through PS-signaling mechanisms to evade immune detection
- PS exposure in the tumor microenvironment is immunosuppressive and increases in response to chemotherapy and radiation therapy
- Bavituximab is an investigational monoclonal antibody that targets PS and is believed to override PS-mediated immunosuppressive signaling in tumors prevalent in the tumor microenvironment, as well as to provide an immune-activating signal through Fc-γ receptor signaling